Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 1/2009

01-12-2009 | Short Report

Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet

Authors: A. I. Dagli, R. T. Zori, H. McCune, T. Ivsic, M. K. Maisenbacher, D. A. Weinstein

Published in: Journal of Inherited Metabolic Disease | Special Issue 1/2009

Login to get access

Summary

Glycogen storage disease type III (GSD III) is caused by a deficiency in debranching enzyme, which leads to an accumulation of abnormal glycogen called limit dextrin in affected tissues. Muscle and liver involvement is present in GSD type IIIa, while the defect is limited to the liver only in GSD type IIIb. Besides skeletal muscle involvement, a cardiomyopathy resembling idiopathic hypertrophic cardiomyopathy is seen. Management consists of maintaining normoglycaemia by supplementation with cornstarch therapy and/or protein. While studies are lacking regarding the best treatment for skeletal muscle disease, a high-protein diet was previously reported to be beneficial. No cases of improvement in cardiomyopathy have been reported. Our patient presented in infancy with hypoglycaemia and hepatomegaly. His prescribed management consisted of cornstarch supplementation and a high-protein diet providing 20% of his total energy needs. At 16 years of age, he developed a severe cardiomyopathy with a left ventricular mass index of 209 g/m2. The cardiomyopathy remained stable on a protein intake of 20–25% of total energy. At age 22 years, the diet was changed to increase his protein intake to 30% of total energy and minimize his cornstarch therapy to only what was required to maintain normoglycaemia. Dramatic improvement in the cardiomyopathy occurred. Over one year, his left ventricular mass index decreased from 159.7 g/m2 to 78 g/m2 (normal 50–86 g/m2) and the creatine kinase levels decreased from 455 U/L to 282 U/L. Avoidance of overtreatment with carbohydrate and a high-protein diet can reverse and may prevent cardiomyopathy.
Literature
go back to reference Akazawa H, Kuroda T, Kim S, Mito H, Kojo T, Shimada K (1997) Specific heart muscle disease associated with glycogen storage disease type III: clinical similarity to the dilated phase of hypertrophic cardiomyopathy. Eur Heart J 18: 532–533.PubMedCrossRef Akazawa H, Kuroda T, Kim S, Mito H, Kojo T, Shimada K (1997) Specific heart muscle disease associated with glycogen storage disease type III: clinical similarity to the dilated phase of hypertrophic cardiomyopathy. Eur Heart J 18: 532–533.PubMedCrossRef
go back to reference Chen YT (2001) Glycogen storage diseases. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 1521–1551. Chen YT (2001) Glycogen storage diseases. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 1521–1551.
go back to reference Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT (1992) Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy. Ann Intern Med 116: 896–900.PubMed Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT (1992) Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy. Ann Intern Med 116: 896–900.PubMed
go back to reference Lee PJ, Deanfield JE, Burch M, Baig K, McKenna WJ, Leonard JV (1997) Comparison of the functional significance of left ventricular hypertrophy in hypertrophic cardiomyopathy and glycogenosis type III. Am J Cardiol 79: 834–838. doi:10.1016/S0002-9149(96)00885-5.PubMedCrossRef Lee PJ, Deanfield JE, Burch M, Baig K, McKenna WJ, Leonard JV (1997) Comparison of the functional significance of left ventricular hypertrophy in hypertrophic cardiomyopathy and glycogenosis type III. Am J Cardiol 79: 834–838. doi:10.​1016/​S0002-9149(96)00885-5.PubMedCrossRef
go back to reference Olson LJ, Reeder GS, Noller KL, Edwards WD, Howell RR, Michels VV (1984) Cardiac involvement in glycogen storage disease III: morphologic and biochemical characterization with endomyocardial biopsy. Am J Cardiol 53: 980–981. doi:10.1016/0002-9149(84)90551-4.PubMedCrossRef Olson LJ, Reeder GS, Noller KL, Edwards WD, Howell RR, Michels VV (1984) Cardiac involvement in glycogen storage disease III: morphologic and biochemical characterization with endomyocardial biopsy. Am J Cardiol 53: 980–981. doi:10.​1016/​0002-9149(84)90551-4.PubMedCrossRef
go back to reference Rossignol AM, Meyer M, Rossignol B, Palcoux MP, Raynaud EJ, Bost M (1979) Glycogenosis type III myocardiopathy. Arch Fr Pediatr 36: 303–309.PubMed Rossignol AM, Meyer M, Rossignol B, Palcoux MP, Raynaud EJ, Bost M (1979) Glycogenosis type III myocardiopathy. Arch Fr Pediatr 36: 303–309.PubMed
go back to reference Shen J, Bao Y, Liu HM, Lee P, Leonard JV, Chen YT (1996) Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest 98: 352–357. doi:10.1172/JCI118799.PubMedCrossRef Shen J, Bao Y, Liu HM, Lee P, Leonard JV, Chen YT (1996) Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest 98: 352–357. doi:10.​1172/​JCI118799.PubMedCrossRef
go back to reference Talente GM, Coleman RA, Alter C, et al (1994) Glycogen storage disease in adults. Ann Intern Med 120: 218–226.PubMed Talente GM, Coleman RA, Alter C, et al (1994) Glycogen storage disease in adults. Ann Intern Med 120: 218–226.PubMed
Metadata
Title
Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet
Authors
A. I. Dagli
R. T. Zori
H. McCune
T. Ivsic
M. K. Maisenbacher
D. A. Weinstein
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue Special Issue 1/2009
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-009-1088-x

Other articles of this Special Issue 1/2009

Journal of Inherited Metabolic Disease 1/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.